Franklin Templeton Investment Funds Sector Equity Franklin Biotechnology Discovery LU0109394709 31 August 2021 Fund

Fund Fact Sheet

For Professional Client Use Only. Not for distribution to Retail Clients. Fund Overview Performance

Base Currency for Fund USD Performance over 5 Years in Share Class Currency (%) Total Net Assets (USD) 2.53 billion Franklin Biotechnology Discovery Fund A (acc) USD Biotechnology Index Fund Inception Date 03.04.2000 200 Number of Issuers 118 180 Benchmark NASDAQ Biotechnology Index 160 Investment Style Sector Morningstar Category™ Sector Equity 140 Biotechnology 120 Summary of Investment Objective The Fund aims to achieve capital appreciation by investing 100 principally in equity securities of biotechnology companies and discovery research firms mainly located in the US. 80 08/16 02/17 08/17 02/18 08/18 02/19 08/19 02/20 08/20 02/21 08/21 Fund Management Discrete Annual Performance in Share Class Currency (%) Evan McCulloch, CFA: United States 08/20 08/19 08/18 08/17 08/16 Wendy Lam, PhD: United States 08/21 08/20 08/19 08/18 08/17 Akiva Felt: United States A (acc) USD 7.90 34.74 -14.76 4.02 21.46 Benchmark in USD 25.46 31.77 -15.82 10.07 18.81 Ratings - A (acc) USD Benchmark in EUR 26.80 21.37 -11.12 12.92 11.32 Overall Morningstar Rating™: Performance in Share Class Currency (%) Asset Allocation Cumulative Annualised Since Since 1 Mth 6 Mths YTD 1 Yr 3 Yrs 10 Yrs Incept 3 Yrs 10 Yrs Incept A (acc) USD 4.86 -6.17 -4.86 7.90 23.91 314.49 329.00 7.41 15.28 7.04 Benchmark in USD 4.09 8.32 12.37 25.46 39.16 438.72 401.99 11.64 18.34 7.83 Benchmark in EUR 4.58 10.69 16.27 26.80 36.78 555.60 306.60 11.00 20.68 6.77 % Category Average 3.58 1.19 2.27 15.43 28.74 289.39 377.05 8.79 14.56 7.57 Equity 96.46 Cash & Cash Equivalents 3.54 Quartile 2 4 4 4 3 3 2 3 3 2 Calendar Year Performance in Share Class Currency (%) 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 A (acc) USD 27.52 33.53 -16.31 16.93 -17.87 4.93 34.70 64.27 26.81 9.60 Benchmark in USD 25.69 24.41 -9.32 21.06 -21.68 11.42 34.32 65.97 32.29 12.08 Benchmark in EUR 15.37 27.11 -5.05 6.17 -19.15 24.12 52.69 59.23 29.75 15.84 Past performance is not an indicator or a guarantee of future performance. The value of shares in the fund and income received from it can go down as well as up, and investors may not get back the full amount invested. All performance data shown is in the currency stated, include reinvested dividends and are net of management fees. Sales charges and other commissions, taxes and other relevant costs paid by the investor are not included in the calculations. Performance may also be affected by currency fluctuations. Currency fluctuations may affect the value of overseas investments. The fund offers other share classes subject to different fees and expenses, which will affect their performance. Please see the prospectus for details. Up to date performance figures can be found on our local website. Top Ten Holdings (% of Total) Fund Measures Issuer Name P/E to Growth 1.84x REGENERON PHARMACEUTICALS INC 5.82 Historical 3 Yr Sales Growth 46.70% INC 4.72 Estimated 3-5 Yr EPS Growth 0.29% ILLUMINA INC 4.53 Price to Earnings (12-mo 16.16x INC 4.50 Forward) PLC 3.81 Standard Deviation (5 Yrs) 22.00% INC 3.62 Sharpe Ratio (5 Yrs) 0.38 INC 3.47 Tracking Error (5 Yrs) 7.09% NOVAVAX INC 3.04 Information Ratio (5 Yrs) -0.47 MIRATI THERAPEUTICS INC 2.98 Beta (5 Yrs) 1.02 INC 2.96 Share Class Information Fees Dividends Fund Identifiers TER (%) Max. Annual Last Paid Last Paid Share Class Incept Date NAV 31.07.2021 Charge (%) Frequency Date Amount Bloomberg ID ISIN A (acc) USD 03.04.2000 USD 42.90 1.81 1.50 N/A N/A N/A TEMBDAI LX LU0109394709

Tel Fax E-Mail Web +352 46 66 67 1 +352 46 66 76 [email protected] www.franklintempleton.lu Franklin Biotechnology Discovery Fund 31 August 2021

For Professional Client Use Only. Not for distribution to Retail Clients. Composition of Fund Market Capitalisation Breakdown in USD % of Equity Performance Attribution by Country <2.0 Billion 21.35 01.09.2020-31.08.2021 Total Effect 2.0-5.0 Billion 15.53 United Kingdom 1.69 5.0-10.0 Billion 15.58 France 0.15 10.0-25.0 Billion 11.13 Israel 0.05 25.0-50.0 Billion 2.52 Belgium -0.02 >50.0 Billion 33.26 Spain -0.03 N/A 0.63 Sweden -0.04 Netherlands -0.08 Performance Attribution by Security Ireland -0.10 01.09.2020-31.08.2021 Total Effect Switzerland -0.16 5 Largest Contributing Securities Canada -0.26 IMMUNOMEDICS INC 2.41 China -0.28 GW PHARMACEUTICALS PLC 2.03 Denmark -0.40 NOVAVAX INC 0.87 Germany -1.67 FATE THERAPEUTICS INC 0.83 United States -13.00 * CORP 0.81 Cash & Cash Equivalents -1.44 5 Smallest Contributing Securities GLOBAL BLOOD THERAPEUTICS INC -0.86 DECIPHERA PHARMACEUTICALS INC -0.98 IOVANCE BIOTHERAPEUTICS INC -1.08 BIONTECH SE -1.43 MODERNA INC -8.69 *Security not held in the portfolio at the end of the reporting period.

Largest Contributing Securities 01.08.2021-31.08.2021 Contribution to Return % Regeneron Pharmaceuticals, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.98 Novavax, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.95 Trillium Therapeutics Inc. Pharmaceuticals Biotechnology & Life Sciences Canada 0.73 Ascendis Pharma A/S Sponsored ADR Pharmaceuticals Biotechnology & Life Sciences Denmark 0.66 PTC Therapeutics, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.32 Gilead Sciences, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.32 Horizon Therapeutics Public Limited Company Pharmaceuticals Biotechnology & Life Sciences United States 0.31 , Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.24 Sutro Biopharma, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.24 Adagio Therapeutics, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0.23 Smallest Contributing Securities 01.08.2021-31.08.2021 Contribution to Return % Public Limited Company Pharmaceuticals Biotechnology & Life Sciences United States -0.62 Illumina, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.43 Amgen Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.34 Reata Pharmaceuticals, Inc. Class A Pharmaceuticals Biotechnology & Life Sciences United States -0.29 Fate Therapeutics, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.21 Zogenix, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.11 Heron Therapeutics Inc Pharmaceuticals Biotechnology & Life Sciences United States -0.10 Arcus Biosciences, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.09 ACADIA Pharmaceuticals Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.09 Silverback Therapeutics, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0.07

What Are the Key Risks? The value of shares in the Fund and income received from it can go down as well as up and investors may not get back the full amount invested. Performance may also be affected by currency fluctuations. Currency fluctuations may affect the value of overseas investments. The Fund invests mainly in equity securities of biotechnology companies. Such securities have historically been subject to significant price movements that may occur suddenly due to market, sector or company-specific factors. As a result, the performance of the Fund can fluctuate very significantly over relatively short time periods. Other significant risks include: securities lending risk, equity risk. For full details of all of the risks applicable to this Fund, please refer to the “Risk Considerations” section of the Fund in the current prospectus of Franklin Templeton Investment Funds. Important Information Issued by Franklin Templeton International Services, S.à r.l. Franklin Templeton Investment Funds (the “Fund”) is a Luxembourg registered SICAV. Source for data and information provided by Franklin Templeton, as of the date of this document, unless otherwise noted. This document does not constitute legal or tax advice nor investment advice or an offer for shares of the Fund. Subscriptions to shares of the Fund can only be made on the basis of the current prospectus and where available, the relevant Key Investor Information Document, accompanied by the latest available audited annual report and semi-annual report accessible on our website at www.franklintempleton.lu or which can be obtained, free of charge, from Franklin Templeton International Services, S.à r.l. - Supervised by the Commission de Surveillance du Secteur Financier - 8A, rue Albert Borschette, L-1246 Luxembourg. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. No shares of the Fund may be directly or indirectly offered or sold to residents of the United States of America. Shares of the Fund are not available for distribution in all jurisdictions and prospective investors should confirm availability with their local Franklin Templeton representative before making any plans to invest. An investment in the Fund entails risks, which are described in the Fund’s prospectus and where available, in the relevant Key Investor Information Document. Special risks may be associated with a Fund’s investment in certain types of securities, asset classes, sectors, markets, currencies or countries and in the Fund’s possible use of derivatives. These risks are more fully described in the Fund’s prospectus and where available, in the relevant Key Investor Information Document and should be read closely before investing. Information is historical and may not reflect current or future portfolio characteristics. All portfolio holdings are subject to change. References to particular industries, sectors or companies are for general information and are not necessarily indicative of a fund's holding at any one time. Benchmark related data provided by FactSet, as of the date of this document, unless otherwise noted. Fund Management: CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. Ratings: © Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Performance: References to indices are made for comparative purposes only and are provided to represent the investment environment existing during the time periods shown. When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark. Top Ten Holdings: These securities do not represent all of the securities purchased, sold or recommended for clients, and the reader should not assume that investment in the securities listed was or will be profitable. The portfolio manager for the Fund reserves the right to withhold release of information with respect to holdings that would otherwise be included in the top holdings list.

© 2021 Franklin Templeton. www.franklintempleton.lu